Is it worth buying Elevance Health stock at a price of $465.8? If this question is on your mind, make sure to check out the fundamentals of this Medical Specialities large-cap company:
-
Elevance Health has logged a -7.0% 52 week change, compared to 24.0% for the S&P 500
-
ELV has an average analyst rating of buy and is -17.34% away from its mean target price of $563.5 per share
-
Its trailing earnings per share (EPS) is $25.72, which brings its trailing Price to Earnings (P/E) ratio to 18.1. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $37.09 and its forward P/E ratio is 12.6
-
The company has a Price to Book (P/B) ratio of 2.85 in contrast to the Health Care sector's average P/B ratio is 4.08
-
ELV has reported YOY quarterly earnings growth of -17.7% and gross profit margins of 0.3%
-
The company's free cash flow for the last fiscal year was $8.25 Billion and the average free cash flow growth rate is 15.3%
-
Elevance Health's revenues have an average growth rate of 10.6% with operating expenses growing at 6.4%. The company's current operating margins stand at 4.6%